Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

Cancer

Volumn 121, Issue 13, 2015, Pages 2185-2192

  Seggewiss Bernhardt, Ruth ^a   Bargou, Ralf C ^a   Goh, Yeow Tee ^b   Stewart, A Keith ^c   Spencer, Andrew ^d   Alegre, Adrian ^e   Bladé, Joan ^f   Ottmann, Oliver G ^g   Fernandez Ibarra, Cristina ^h   Lu, Hong ^h   Pain, Scott ^h   Akimov, Mikhail ^h   Iyer, Swaminathan Padmanabhan ⁱ  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c MAYO CLINIC   (United States)

^d MONASH UNIVERSITY   (Australia)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g GOETHE UNIVERSITY   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

AUY922; bortezomib; heat shock protein 90; heat shock protein 90 inhibitors; proteasome inhibitor; relapsed or refractory multiple myeloma

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LUMINESPIB; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; RESORCINOL DERIVATIVE;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CATARACT; CLINICAL ARTICLE; CONFERENCE PAPER; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; EYE TOXICITY; FATIGUE; FEMALE; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NIGHT BLINDNESS; NIGHT SWEAT; NONCARDIAC CHEST PAIN; OPEN STUDY; OPTIC NERVE DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHOTOPSIA; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RETINOPATHY; RHINOPHARYNGITIS; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT; VOLUME OF DISTRIBUTION; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; METABOLISM; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MALE; MULTIPLE MYELOMA; RESORCINOLS;

EID: 84931069759     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29339     Document Type: Conference Paper

References (24)

1. Saini N, Mahindra A,. Therapeutic strategies for the treatment of multiple myeloma. Discov Med. 2013; 15: 251-258.
2. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P,. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008; 22: 231-239.
3. Chatterjee M, Jain S, Stuhmer T, et al., STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood. 2007; 109: 720-728.
4. Peterson LB, Blagg BS,. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem. 2009; 1: 267-283.
5. Trepel J, Mollapour M, Giaccone G, Neckers L,. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10: 537-549.
6. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R,. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013; 39: 375-387.
7. Pearl LH, Prodromou C, Workman P,. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 2008; 410: 439-453.
8. Brough PA, Aherne W, Barril X, et al., 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem. 2008; 51: 196-218.
9. Eccles SA, Massey A, Raynaud FI, et al., NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008; 68: 2850-2860.
10. Goetz MP, Toft D, Reid J, et al., Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005; 23: 1078-1087.
11. Grem JL, Morrison G, Guo XD, et al., Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005; 23: 1885-1893.
12. Richardson PG, Sonneveld P, Schuster MW, et al., Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
13. San Miguel JF, Schlag R, Khuageva NK, et al., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
14. Stuhmer T, Zollinger A, Siegmund D, et al., Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008; 22: 1604-1612.
15. McMillin DW, Negri J, Delmore J, et al., Activity of new heat shock protein 90 (hsp90) inhibitor NVP-AUY922 against myeloma cells sensitive and resistant to conventional agents. ASH Annu Meet Abstr. 2007; 110: 1587.
16. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC,. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011; 152: 367-379.
17. Durie BG, Harousseau JL, Miguel JS, et al., International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
18. Babb J, Rogatko A, Zacks S,. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998; 17: 1103-1120.
19. Sessa C, Shapiro GI, Bhalla KN, et al., First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013; 19: 3671-3680.
20. Gao Z, Garcia-Echeverria C, Jensen MR,. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel. 2010; 13: 193-202.
21. Jhaveri K, Taldone T, Modi S, Chiosis G,. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012; 1823: 742-755.
22. Zhou D, Liu Y, Ye J, et al., A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol Appl Pharmacol. 2013; 273: 401-409.
23. Reece DE, Sullivan D, Lonial S, et al., Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011; 67: 57-67.
24. Davenport EL, Zeisig A, Aronson LI, et al., Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia. 2010; 24: 1804-1807.